Reimagining ADCs.
Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.
Antibody Drug Conjugates and Targeted Therapy
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
Seventure Partners Startup accelerator & VC, Venture Capital and Private Equity Principals | Seventure Partners Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 18 Mar 2024 | | |
Bristol Myers Squibb Pharmaceutical, Pharmaceutical Manufacturing | Bristol Myers Squibb Pharmaceutical, Pharmaceutical Manufacturing | Other 20 Apr 2023 | |